| 000 | 01555 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515093227.0 | ||
| 264 | 0 | _c20080731 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a1368-5031 | ||
| 024 | 7 |
_a10.1111/j.1742-1241.2007.01625.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStaskin, D R | |
| 245 | 0 | 0 |
_aEffects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. _h[electronic resource] |
| 260 |
_bInternational journal of clinical practice _cJan 2008 |
||
| 300 |
_a27-38 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Cutaneous |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aHealth Status Indicators |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMandelic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscarinic Antagonists _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aProstatic Hyperplasia _xcomplications |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrinary Bladder, Overactive _xdrug therapy |
| 700 | 1 | _aRosenberg, M T | |
| 700 | 1 | _aDahl, N V | |
| 700 | 1 | _aPolishuk, P V | |
| 700 | 1 | _aZinner, N R | |
| 773 | 0 |
_tInternational journal of clinical practice _gvol. 62 _gno. 1 _gp. 27-38 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1742-1241.2007.01625.x _zAvailable from publisher's website |
| 999 |
_c17501468 _d17501468 |
||